Breast cancer recurrence according to molecular subtype

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 14, 2014, Pages 5539-5544

  Shim, Hee Jin ^a   Kim, Sung Hun ^a   Kang, Bong Joo ^a   Choi, Byung Gil ^a   Kim, Hyeon Sook ^b   Cha, Eun Suk ^c   Song, Byung Joo ^a  

^a The Catholic University of Korea   (South Korea)

^b The Catholic University of Korea   (South Korea)

^c Ewha Womans University   (South Korea)

Author keywords

Breast neoplasms; Estrogen; Receptors; Recurrence; Triple negative breast neoplasms; Ultrasonography

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; TUMOR MARKER;

ADULT; FEMALE; HUMAN; LYMPH NODE METASTASIS; METABOLISM; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; RADIOGRAPHY; TRIPLE NEGATIVE BREAST NEOPLASMS;

ADULT; FEMALE; HUMANS; KI-67 ANTIGEN; LYMPHATIC METASTASIS; NEOPLASM RECURRENCE, LOCAL; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84905977876     PISSN: 15137368     EISSN: None     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.14.5539     Document Type: Article

References (16)

1. Bessonova L, Taylor TH, Mehta RS, et al. (2011). Risk of a second breast cancer associated with hormone-receptor and HER2/neu status of the first breast cancer. Cancer Epidemiol Biomarkers Prev, 20, 389-96.
2. García Fernández A, Giménez N, Fraile M, et al. (2012). Survival and clinicopathological characteristics of breast cancer patient according to different tumour subtypes as determined by hormone receptor and Her2 immunohistochemistry. a single institution survey spanning 1998 to 2010. Breast, 21, 366-73.
3. Goldhirsch A, Wood WC, Coates AS, et al. (2011). Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen international expert consensus on the primary therapy of early breast cancer 2011. Ann Oncol, 22, 1736-47.
4. Gordon PB, Goldenberg SL (1995). Malignant breast masses detected only by ultrasound. A retrospective review. Cancer, 76, 626-30.
5. Haffty BG, Yang Q, Reiss M, et al. (2006). Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol, 24, 5652-7.
6. Houssami N, Ciatto S, Martinelli F, et al. (2009). Early detection of second breast cancers improves prognosis in breast cancer survivors. Ann Oncol, 20, 1505-10.
7. Kadivar M, Mafi N, Joulaee A, et al. (2012). Breast cancer molecular subtypes and associations with clinicopathological characteristics in Iranian women, 2002-2011. Asian Pac J Cancer Prev, 13, 1881-6.
8. Kim HJ, Kwak JY, Choi JW, et al. (2010). Impact of US surveillance on detection of clinically occult locoregional recurrence after mastectomy for breast cancer. Ann Surg Oncol, 17, 2670-6.
9. Lowery AJ, Kell MR, Glynn RW, et al. (2012). Locoregional recurrence after breast cancer surgery: a systematic review by receptor phenotype. Breast Cancer Res Treat, 133, 831-41.
10. Malone KE, Begg CB, Haile RW, et al. (2010). Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2. J Clin Oncol, 28, 2404-10.
11. Najafi B, Anvari S, Roshan ZA (2013). Disease free survival among molecular subtypes of early stage breast cancer between 2001 and 2010 in Iran. Asian Pac J Cancer Prev, 14, 5811-6.
12. Sørlie T, Perou CM, Tibshirani R, et al. (2001). Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA, 98, 10869-74.
13. Spitale A, Mazzola P, Soldini D, et al. (2009). Breast cancer classification according to immunohistochemical markers: clinicopathologic features and short-term survival analysis in a population-based study from the South of Switzerland. Ann Oncol, 20, 628-35.
14. Tun NM, Villani GM, Ong K (2011). Risk of having BRCA mutations in women with triple-negative breast cancer: a systematic review and meta-analysis. J Clin Oncol, 29, 160.
15. Van T, Veer LJ, Dai H, De Vijver VMJ, et al. (2002). Gene expression profiling predicts clinical outcome of breast cancer. Nature, 415, 530-6.
16. Voduc KD, Cheang MC, Tyldesley S, et al. (2010). Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol, 28, 1684-91.